Magnetic Resonance Imaging in Multiple Sclerosis

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2018 Jan 24

PMID 29358319

Citations 36

Authors

Christopher C Hemond

Rohit Bakshi

Affiliations

Soon will be listed here.

Abstract

Since its technical development in the early 1980s, magnetic resonance imaging (MRI) has quickly been adopted as an essential tool in supporting the diagnosis, longitudinal monitoring, evaluation of therapeutic response, and scientific investigations in multiple sclerosis (MS). The clinical usage of MRI has increased in parallel with technical innovations in the technique itself; the widespread adoption of clinically routine MRI at 1.5T has allowed sensitive qualitative and quantitative assessments of macroscopic central nervous system (CNS) inflammatory demyelinating lesions and tissue atrophy. However, conventional MRI lesion measures lack specificity for the underlying MS pathology and only weakly correlate with clinical status. Higher field strength units and newer, advanced MRI techniques offer increased sensitivity and specificity in the detection of disease activity and disease severity. This review summarizes the current status and future prospects regarding the role of MRI in the characterization of MS-related brain and spinal cord involvement.

Citing Articles

Impact of Physical Activity on Cellular Metabolism Across Both Neurodegenerative and General Neurological Conditions: A Narrative Review.

Clemente-Suarez V, Rubio-Zarapuz A, Belinchon-deMiguel P, Beltran-Velasco A, Martin-Rodriguez A, Tornero-Aguilera J Cells. 2024; 13(23).

PMID: 39682689 PMC: 11640500. DOI: 10.3390/cells13231940.

Exploring Spinal Cord Changes in Multiple Sclerosis Patients Using MRI.

Alrehaili A, Faizo N, Alsulimani B, Alsulimani R, Aldwaila D, Alqarni N NeuroSci. 2024; 5(1):87-97.

PMID: 39483810 PMC: 11523708. DOI: 10.3390/neurosci5010006.

The Probable Infectious Origin of Multiple Sclerosis.

Landry R, Embers M NeuroSci. 2024; 4(3):211-234.

PMID: 39483197 PMC: 11523707. DOI: 10.3390/neurosci4030019.

Diffuse white matter pathology in multiple sclerosis during treatment with dimethyl fumarate-An observational study of changes in normal-appearing white matter using proton magnetic resonance spectroscopy.

Tisell A, Soderberg K, Link Y, Lundberg P, Mellergard J PLoS One. 2024; 19(10):e0309547.

PMID: 39432495 PMC: 11493296. DOI: 10.1371/journal.pone.0309547.

Quantitative Analysis of Early White Matter Damage in Cuprizone Mouse Model of Demyelination Using 7.0 T MRI Multiparametric Approach.

Friesen E, Sheft M, Hari K, Palmer V, Zhu S, Herrera S ASN Neuro. 2024; 16(1):2404366.

PMID: 39400556 PMC: 11792140. DOI: 10.1080/17590914.2024.2404366.

References

Masdeu J, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P . Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology. 2000; 54(7):1427-33. DOI: 10.1212/wnl.54.7.1427. View

van Walderveen M, Lycklama A Nijeholt G, Ader H, Jongen P, Polman C, Castelijns J . Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol. 2001; 58(1):76-81. DOI: 10.1001/archneur.58.1.76. View

Khalil M, Enzinger C, Langkammer C, Tscherner M, Wallner-Blazek M, Jehna M . Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler. 2009; 15(9):1048-54. DOI: 10.1177/1352458509106609. View

Neema M, Stankiewicz J, Arora A, Dandamudi V, Batt C, Guss Z . T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging. 2007; 17 Suppl 1:16S-21S. DOI: 10.1111/j.1552-6569.2007.00131.x. View

Neema M, Arora A, Healy B, Guss Z, Brass S, Duan Y . Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009; 19(1):3-8. PMC: 2762230. DOI: 10.1111/j.1552-6569.2008.00296.x. View

Mistry N, Abdel-Fahim R, Samaraweera A, Mougin O, Tallantyre E, Tench C . Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions. Mult Scler. 2015; 22(10):1289-96. DOI: 10.1177/1352458515616700. View

Zivadinov R, Heininen-Brown M, Schirda C, Poloni G, Bergsland N, Magnano C . Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage. 2011; 59(1):331-9. DOI: 10.1016/j.neuroimage.2011.07.045. View

Weiner H . The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann Neurol. 2009; 65(3):239-48. DOI: 10.1002/ana.21640. View

Stojanov D, Aracki-Trenkic A, Benedeto-Stojanov D . Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Neuroradiology. 2016; 58(5):433-41. DOI: 10.1007/s00234-016-1658-1. View

10.

Gaitan M, Shea C, Evangelou I, Stone R, Fenton K, Bielekova B . Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol. 2011; 70(1):22-9. PMC: 3143223. DOI: 10.1002/ana.22472. View

11.

Peterson J, Bo L, Mork S, Chang A, Trapp B . Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001; 50(3):389-400. DOI: 10.1002/ana.1123. View

12.

Alexander A, Lee J, Lazar M, Field A . Diffusion tensor imaging of the brain. Neurotherapeutics. 2007; 4(3):316-29. PMC: 2041910. DOI: 10.1016/j.nurt.2007.05.011. View

13.

van de Pavert S, Muhlert N, Sethi V, Wheeler-Kingshott C, Ridgway G, Geurts J . DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?. J Neurol Neurosurg Psychiatry. 2015; 87(5):461-7. PMC: 4853554. DOI: 10.1136/jnnp-2014-310142. View

14.

Stankiewicz J, Neema M, Alsop D, Healy B, Arora A, Buckle G . Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study. J Neurol Sci. 2009; 279(1-2):99-105. PMC: 2679653. DOI: 10.1016/j.jns.2008.11.009. View

15.

Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese I . Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015; 85(1):18-28. PMC: 4501940. DOI: 10.1212/WNL.0000000000001587. View

16.

Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J . Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol. 1999; 20(9):1619-27. PMC: 7056180. View

17.

Bakshi R, Neema M, Healy B, Liptak Z, Betensky R, Buckle G . Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008; 65(11):1449-53. PMC: 2762216. DOI: 10.1001/archneur.65.11.1449. View

18.

Roosendaal S, Moraal B, Pouwels P, Vrenken H, Castelijns J, Barkhof F . Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler. 2009; 15(6):708-14. DOI: 10.1177/1352458509102907. View

19.

Leary S, Davie C, Parker G, Stevenson V, Wang L, Barker G . 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol. 2000; 246(11):1023-6. DOI: 10.1007/s004150050507. View

20.

Radue E, Barkhof F, Kappos L, Sprenger T, Haring D, de Vera A . Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology. 2015; 84(8):784-93. PMC: 4339126. DOI: 10.1212/WNL.0000000000001281. View